Form 4: Evoke Pharma Director Greg Pyszczymuka Acquires Stock Options

Director Greg Pyszczymuka of Evoke Pharma, Inc. reports the acquisition of stock options exercisable for 1,155 shares of common stock.

Summary

• Greg Pyszczymuka, a director of Evoke Pharma, Inc., filed a Form 4 on May 22, 2025.
• The report details the acquisition of stock options to purchase 1,155 shares of Evoke Pharma's common stock at an exercise price of $3.453.
• These options were granted on May 21, 2025, and vest one year from the grant date, contingent upon continued service to the company.
• Following this transaction, Pyszczymuka directly owns 6,988 derivative securities.
• The options expire on May 20, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans to align management's interests with those of shareholders.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates

Keywords

Evoke Pharma, Stock Options, Form 4, Director, Pyszczymuka, Beneficial Ownership, Securities